Navigation Links
Novel compound may lessen heart attack damage
Date:2/7/2008

DURHAM, NC A novel drug designed to lessen muscle damage from a heart attack has passed initial safety tests at the Duke Clinical Research Institute. Results of the study, available online and to be published in the February 19 issue of the journal Circulation, reflect the first time the drug has been tested in humans.

The drug, known as KAI-9803, blocks the activity of an enzyme called delta protein kinase C that triggers cell and tissue death in the aftermath of percutaneous coronary intervention, or PCI. PCI is a set of procedures including balloon angioplasty and stent placement that clear and prop open clogged coronary blood vessels that lead to a heart attack a process known as reperfusion.

Although the trial (known as DELTA-MI) was not designed to demonstrate the efficacy of KAI-9803, researchers say early data suggest it appears to be a promising compound.

Weve needed something like this for a long time, says Dr. Matthew Roe, a cardiologist at Duke and the lead investigator of the trial.

Roe says many people may not realize that the heart suffers damage at two major points in a heart attack: first, when a blockage in a coronary artery prevents blood and oxygen from getting to the heart, and then again when the patient undergoes PCI and normal blood flow is restored through reperfusion.

We may not be able to intervene in the first stage of a heart attack, but we think there may be ways to limit damage caused by reperfusion injury, he says.

Researchers randomized 154 patients who had suffered heart attacks and were eligible for PCI into either one of four dosing levels of KAI-9803 or a placebo. Patients underwent PCI with physicians injecting the drug directly into their coronary blood vessels during the procedure.

The goal of the treatment is to flood the heart damaged by the heart attack with the drug immediately before blood flow is restored and then again, immediately afterwards, says Roe. We believe that bathing the area with this novel compound may block the damaging cascade of events that are triggered specifically by delta protein kinase C when blood is restored to the heart muscle, he says.

Earlier studies in animals showed that KAI-9803 lessened damage to the heart muscle and quickly restored its pumping function.

We designed the DELTA MI trial to find out if KAI-9803 is safe for humans, and we accomplished that goal; we did not see any serious side effects, says Roe. We also found, however, many promising signs of beneficial drug activity such as lessened damage to the heart muscle and improvement in electrical conductivity in the heart that corresponded to restoration of blood flow to the heart muscle. As a result, we feel this drug has the potential to be helpful in reducing the impact of a heart attack in humans.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Novel molecules developed at UB can boost vaccine potency
2. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
3. Novel vaccine concept developed by scientists at the Wistar Institute
4. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
5. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
6. Statement by AARP CEO Bill Novelli on President Bushs State of the Union
7. New method enables design, production of extremely novel drugs
8. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
9. Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi-Electrode Ablation System
10. Novel anticancer strategy moves from laboratory to clinic
11. FDA approves Bystolic, a novel beta blocker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... medical device sectors, today announced the winners of its 3rd Annual ELITE Awards. ... most influential people in the healthcare industry today. , Out of more than ...
(Date:5/23/2017)... ... 2017 , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations ... Rory Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s ... ) today reported on a new study released on May 21, 2017 in the ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National Council on ... to announce the organization’s Certified Strength Coach credential has earned accreditation from the ... program validates the competency of qualified candidates for jobs in the Strength and ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a ... in building collagen and elastin in their face, neck, and body through a ...
(Date:5/23/2017)... NV (PRWEB) , ... May 23, 2017 , ... ... Dental Specialists, are educating patients on peri-implantitis in Las Vegas, NV, ... to receive a custom gum disease consultation and leading care for peri-implantitis, with ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/9/2017)... Ore. , May 9, 2017  Semler ... that provides technology solutions to improve the clinical ... financial results for the first quarter ended March ... our products enable our customers to identify when ... to intervene before events like heart attacks or ...
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
Breaking Medicine Technology: